Eli Lilly and Company (LLY)

A central part of Lilly’s current profile is its cardiometabolic portfolio. Mounjaro, used for type 2 diabetes, and Zepbound, used for chronic weight management, are based on tirzepatide and have become major growth drivers as demand for GLP-1 and related incretin therapies increases. Lilly also markets established diabetes products such as Trulicity, Jardiance, Humalog, and Humulin, giving it broad exposure across modern and legacy diabetes treatment.

Beyond metabolic disease, Lilly has important positions in cancer and immunology. Verzenio is used in certain breast cancer settings, while Jaypirca targets specific blood cancers. Taltz and Olumiant are part of the company’s immunology franchise, addressing inflammatory and autoimmune conditions. In neuroscience, Lilly is active in areas such as Alzheimer’s disease and migraine, supported by a research pipeline that aims to produce differentiated therapies for complex neurological disorders.

The company’s investment case is closely tied to product innovation, clinical trial execution, regulatory approvals, manufacturing capacity, and pricing dynamics. Lilly competes with other large drugmakers but stands out for the scale of its obesity and diabetes opportunity, its strong research base, and its ability to turn specialised medicines into global commercial franchises.